Bioassay-guided fractionation led to the discovery of a novel neo-clerodane diterpenoid, scutebarbalactone VN (BalA: 8,, from the methanol extract of the whole-plant of Vietnamese Scutellaria barbata D. Don. A microarray technique combined with bioinformatic analyses showed that BalA could inhibit cell cycle pathways by downregulating genes such as CDC25A and AURKA. BalA also showed the potential to reactivate downregulated genes in hepatocellular carcinoma cells and genes in antioxidant pathways such as HMOX1 and HSPA1A. Querying Connectivity map 2.0 resulted in a match of the BalA-modulated gene signature with that of 10 known compounds, most of which are currently marketed chemotherapy drugs. The highest matching scores belonged to lomustine, semustine, and withaferin A. Lomustine and semustine were found to alkylate DNA and RNA, while withaferin A inhibits nuclear factor kappa B (NF-κB) activity. A luciferase reporter assay was also conducted on 293/NF-κB human embryonic kidney cells that had been transfected with the NF-κB-luciferase plasmid to verify the anticancer activity of BalA. The assay showed that Ba1A effectively blocked NF-κB with an IC 50 of 38.6 ± 0.05 μM.
The herb Ban-chi-lien (Scutellaria barbata D. Don, Lamiaceae) is prevalent in tropical and subtropical zones of Asia, including Japan, Korea, China, Nepal, India, Myanmar, Vietnam, Laos, and Thailand. This plant is particularly abundant in the northern provinces of Vietnam. This same herbal material, "Ban-Zhi-Lian", is also a popular ingredient in traditional Chinese medicine used as a treatment for pain and swelling of the throat, edema and hemorrhoids, cancer, inflammation, and urinary disease [1] .
Because of its widespread use and efficacy, the chemical composition of Chinese and Vietnamese S. barbata has been recently examined, and more than 130 compounds, including a large number of flavonoids, unique neo-clerodane alkaloids and diterpenoids, essential oils, and polysaccharides were obtained. Among them, the flavonoids and neo-clerodane diterpenoids and alkaloids were found to contribute most to the pharmacological efficacy of S. barbata [1] . Crude extracts of S. barbata have been demonstrated to induce apoptosis in prostate cancer cells [2] , arrest G1/S transition through the modulation of p53 and Akt pathways in human colon carcinoma cells [3] , and prevent tumorigenesis in rat liver [4] . This plant has also been tested in phase-1B dose escalation trials in patients with metastatic breast cancer with very minor side effects [5] .
A new neo-clerodane diterpenoid, scutebarbalactone VN (BalA), isolated from Vietnamese S. barbata has shown promising inhibitory effects on aromatase and Oct4 gene expression, as well as significant cytotoxicity against a panel of cancer cell lines [6] . As a part of our ongoing investigations of Ba1A, the current paper explores its pharmacological activities at the molecular level and its activity against NF-B.
Pathway and GSEA analysis of BalA
L1000 microarray data of BalA in HepG2 cell lines revealed 468 upregulated and 241 downregulated probe sets (Supplementary Tables S1 and S2) that were identified by t-tests. The top 50 up-and downregulated probe sets are shown in Figure 1 . Pathway analyses showed that the upregulated genes enriched antioxidant and tumor suppressor pathways while the downregulated genes mainly enriched cell cycle-related pathways ( Table 1 and 2). For example, HMOX1 and HSPA1A were upregulated, suggesting the reactivation of antioxidant pathways. In contrast, the downregulation of CDC25A and AURKA suggested the inhibition of cell cycle pathways. Gene Set Enrichment Analyses (GSEA) showed that gene sets related to the cell cycle had negative enrichment scores, while a downregulated gene set in hepatocellular carcinoma cells (HCCs) had a positive enrichment score (Figure 2 ), implying that BalA may have a role in inhibiting the cell cycle, reducing oxidative stress, and/or reactivating downregulated genes in HCCs. In addition, BalA exhibited a strong cytotoxic effect against HCCs [IC 50 (the concentration required to inhibit the HCCs' growth by 50%) of 1.16 ± 0.03 μg/mL)], as demonstrated in sulforhodamine B assays ( Supplementary Table S3 ).
Connectivity map database link
Up-and downregulated gene signatures were extracted from the L1000 microarray data of BalA in HepG2 cells to query Connectivity map (Cmap) 2.0. Most of the top 10 highest scoring compounds are currently marketed anticancer drugs (Table 3 ).
Based on the Cmap 2.0 query, the anticancer activity of BalA was similar to those of lomustine, semustine, and withaferin A. Lomustine and semustine are currently sold as chemotherapy drugs to treat brain tumors and Hodgkin's disease through the alkylation of DNA and RNA, while withaferin A inhibits the transcription factors of both nuclear factor kappa B (NF-κB) and Sp1, downregulates VEGF gene expression, and affects calcium signaling.
NF-kB inhibition activity of BalA
Luciferase reporter assays were conducted on 293/NF-B human embryonic kidney cells that had been transfected with NF-κBluciferase plasmid to determine the effectiveness of NF-B inhibition by BalA. The results showed that BalA was as an effective inhibitor of NF-B with an IC 50 of 38.60 ± 0.05 μM (Figure 3 ). NF-κB comprises a family of transcription factors that have been shown to regulate the expression of several genes involved in immune and inflammatory responses, antioxidant activities, and cancer. NF-κB activation has been connected to many aspects of oncogenesis and cancer through the control of apoptosis, cell cycle, cell differentiation, and cell migration [7] . Several studies have suggested that blocking the NF-κB signaling pathway can cause tumor cells to cease proliferation, die, or become more sensitive to the action of antitumor agents. Therefore, the inhibition of NF-B activation has become a potential target of cancer therapies [8], and many natural compounds have been found to inhibit NF-κB, including ectinascidin 743, cucurmin, resveratrol, and digitoxin [9] . The inhibition of NF-B by BalA has been determined using NF-κB luciferase reporter assay. Resveratrol, the positive control, strongly induces apoptosis in cancer cells by inhibiting nitric oxide production and activation of the COX-2 enzyme in the NF-κB signaling pathway through the suppression of p65 and IB kinase [10] . In this study, we investigated the inhibition of NF-κB activation by Ba1A using a luciferase reporter gene. Resveratrol inhibited NF-κB activation with an IC 50 of 26.1 µM. BalA showed a significant inhibitory effect with an IC 50 of 38.6 µM. These data suggest that BalA prevents the binding of NF-κB to its target gene. 
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